ReviewMedical oncology (Northwood, London, England)2013
Triple-negative breast cancer: new perspectives for novel therapies.
Review in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- WTAP Mediates NUPR1 Regulation of LCN2 Through mBiochemical genetics · 2024Article
- A feedback loop between lncRNA MALAT1 and DNMT1 promotes triple-negative breast cancer stemness and tumorigenesis.Cancer biology & therapy · 2023Article
- A review of the impact of energy balance on triple-negative breast cancer.Journal of the National Cancer Institute. Monographs · 2023Review
- YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer.Gland surgery · 2021Article
- Development of a 15-Gene Signature Model as a Prognostic Tool in Sex Hormone-Dependent Cancers.BioMed research international · 2021Article
- Cathepsin L interacts with CDK2-AP1 as a potential predictor of prognosis in patients with breast cancer.Oncology letters · 2020Article
- Effects of CORO2A on Cell Migration and Proliferation and Its Potential Regulatory Network in Breast Cancer.Frontiers in oncology · 2020Article
- Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.Translational oncology · 2019Article
- First international TNBC conference meeting report.Breast cancer research and treatment · 2018Article
- Targeting the Stem Cell Properties of Adult Breast Cancer Cells: Using Combinatorial Strategies to Overcome Drug Resistance.Current molecular biology reports · 2017Article
- Frizzled7 Antibody-Functionalized Nanoshells Enable Multivalent Binding for Wnt Signaling Inhibition in Triple Negative Breast Cancer Cells.Small (Weinheim an der Bergstrasse, Germany) · 2017Article
- Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.Breast cancer research : BCR · 2016Article
- New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.Cell cycle (Georgetown, Tex.) · 2016Article
- Do signal transduction cascades influence survival in triple-negative breast cancer? A preliminary study.OncoTargets and therapy · 2016Article
- The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells.Oncotarget · 2015Article
- Preferential, enhanced breast cancer cell migration on biomimetic electrospun nanofiber 'cell highways'.BMC cancer · 2014Article
- Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) represents 10-20 % of all mammary tumors. It is often found in younger women and has been associated with poor prognosis, due to aggressive tumor phenotype(s), early metastasis to visceral organ or brain after chemotherapy and present lack of clinically established targeted therapies. In recent years, a greater understanding of the biology of this disease has led to the development of numerous and varied therapeutic approaches, especially the trials on poly (ADP-ribose) polymerase inhibitors BSI-201 and olaparib, and antiangiogenic agents such as bevacizumab and sunitinib, which have raised hopes in the treatment for TNBC and BRCA1/2-positive disease. But should these trials fail, what are the new possible perspectives we have in our hand to fight this disease? In the current review, we will assess mainly the possible future targeted therapeutic strategies, which could be the answer to our question in TNBC. Recent studies have shown several markers, which have roles in TNBC that could be possible targets for therapy. Some of these markers are p53-induced miR-205, leptin receptor antagonist peptide, enhancer of zeste homolog 2 and Notch 1 pathway components, each of them could offer different mechanism for target therapy in TNBC. Last but not least, vaccinia virus GLV-1h153 has shown exciting result in treating and preventing metastatic triple-negative breast cancer.
Indexed as
Identifiers
23824643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.